US › Healthcare

Adicet Bio Inc (ACET)

US · Healthcare · Biotechnology

$9.21-0.32%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-20.2M
Profit YoY
+28.2%
EPS
$-1.88
EPS estimate
$-3.08

EPS came in at -1.88 against a street estimate of -3.08 — a beat of 39.0%.

Key statistics

Market cap
$85.2M
Forward P/E
0.0
P/B
0.61
Book value
$13.03
EPS (TTM)
$-13.87
52-week high
$17.44
52-week low
$6.01
50-day MA
$8.29
200-day MA
$8.55
Beta
1.59

Analyst view

Analysts rate Adicet Bio Inc a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $35.50.

Shareholding

Insiders
1.08%
Institutions
63.33%

Largest institutional holders

FundStake
RA Capital Management, LLC12.65%
Orbimed Advisors, LLC11.00%
Franklin Resources Inc6.70%
Citadel Advisors Llc4.08%
Vanguard Capital Management, LLC3.60%
Woodline Partners LP3.35%
Adage Capital Partners Gp LLC2.94%
Prosight Management, LP2.68%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Adicet Bio Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.